Publications by authors named "Jorg Ruof"

Claim this Profile
A
Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy.
Elaine Julian, Tom Belleman, Maria João Garcia, Maureen Rutten-van Mölken, Robin Doeswijk, Jörg Ruof

J Mark Access Health Policy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technology Assessment vs. Technology Appraisal-How to Strengthen the Science/Value Dichotomy with EU HTA?
Sandro Gsteiger, Heiner C Bucher, James Ryan, Jörg Ruof

J Mark Access Health Policy· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy.
Elaine Julian, Oriol Solà-Morales, Maria João Garcia, Francine Brinkhuis, Mira Pavlovic, Jörg Ruof

J Mark Access Health Policy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Jörg Ruof

Health Res Policy Syst· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Jörg Ruof

J Mark Access Health Policy· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of stakeholder involvement in the evolving EU HTA process: .
Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens

J Mark Access Health Policy· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy.
Elaine Julian, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Jörg Ruof

Health Econ Rev· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology-Based Tool to Support and Review Registries.
Alexander Allen, Hannah Patrick, Jorg Ruof, Barbara Buchberger, Leonor Varela-Lema

Value Health· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology.
Elaine Julian, Fabrizio Gianfrate, Oriol Sola-Morales, Peter Mol, Jean-François Bergmann, Jörg Ruof

Health Econ Rev· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Julia Annabel Wagle, Jan-Paul Flacke, Dietrich Knoerzer, Jörg Ruof, Sonja Merkesdal

Value Health· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Thomas R Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J-Matthias Graf von der Schulenburg, Jörg Ruof

Health Econ Rev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
Giovanni Giuliani, Frederic Chassagnol, David Traub, Marlene Gyldmark, Ansgar Hebborn, Jörg Ruof

Health Econ Rev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Georg Isbary, Thomas R Staab, Volker E Amelung, Charalabos-Markos Dintsios, Christof Iking-Konert, Jörg Ruof

Value Health· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
Marlene Gyldmark, Kristian Lampe, Jörg Ruof, Johannes Pöhlmann, Ansgar Hebborn

Int J Technol Assess Health Care· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making.
Evelyn Schlegl, Pierre Ducournau, Jörg Ruof

Pharmaceut Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Jörg Ruof, Thomas Staab, Charalabos-Markos Dintsios, Jakob Schröter, Friedrich Wilhelm Schwartz

Health Econ Rev· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
Thomas Staab, Georg Isbary, Volker E Amelung, Jörg Ruof

BMC Health Serv Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The influence of framework conditions for integrated care programs on their potential of evaluation].
Svenja Jacobs, Justyna Hartmann, Sveja Eberhard, Jörg Ruof, Volker Eric Amelung

Z Evid Fortbild Qual Gesundhwes· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Jörg Ruof, Olivier Flückiger, Niko Andre

Drugs R D· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
Jörg Ruof, Dietrich Knoerzer, Anja-Alexandra Dünne, Charalabos-Markos Dintsios, Thomas Staab

Health Policy· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
Jörg Ruof, Friedrich Wilhelm Schwartz, J-Matthias Schulenburg, Charalabos-Markos Dintsios

Eur J Health Econ· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.
Jörg Ruof, Charalabos-Markos Dintsios, Friedrich Wilhelm Schwartz

Value Health· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
Inna Dabisch, Jürgen Dethling, Charalabos-Markos Dintsios, Melanie Drechsler, Daniel Kalanovic, Jörg Ruof

Health Econ Rev· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
Timm Kirchhoff, Jörg Ruof, Thomas Mittendorf, Markus Rihl, Michael Bernateck

Rheumatology (Oxford)· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Jörg Ruof, Alexander Dusek, Michael DeSpirito, Ralph A Demasi

Clin Drug Investig· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis